News Image

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Provided By GlobeNewswire

Last update: May 12, 2025

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years

Read more at globenewswire.com

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (7/25/2025, 8:00:01 PM)

After market: 49.03 -0.7 (-1.4%)

49.725

+5.01 (+11.19%)



Find more stocks in the Stock Screener

Follow ChartMill for more